Comparing the long-term clinical and economic impact of ofatumumab versus dimethyl fumarate and glatiramer acetate in patients with relapsing multiple sclerosis: A cost-consequence analysis from a societal perspective in Germany

BACKGROUND: Evidence suggests that early highly efficacious therapy in relapsing multiple sclerosis is superior to escalation strategies. OBJECTIVE: A cost-consequence analysis simulated different treatment scenarios with ofatumumab (OMB), dimethyl fumarate (DMF) and glatiramer acetate (GA): immedia...

Descripción completa

Detalles Bibliográficos
Autores principales: Koeditz, Dominik, Frensch, Juergen, Bierbaum, Martin, Ness, Nils-Henning, Ettle, Benjamin, Vudumula, Umakanth, Gudala, Kapil, Adlard, Nicholas, Tiwari, Santosh, Ziemssen, Tjalf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8969034/
https://www.ncbi.nlm.nih.gov/pubmed/35371535
http://dx.doi.org/10.1177/20552173221085741

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8969034/
https://www.ncbi.nlm.nih.gov/pubmed/35371535
http://dx.doi.org/10.1177/20552173221085741

Ejemplares similares